Revenue segments as reported by the company.

Collaboration revenue

Grant revenue

Product sales

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and Development

General and Administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Moderna

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Moderna reports robust earnings, eyes growth through innovative vaccines

Moderna's strong financial performance and strategic investments in R&D and commercial activities position it well for future growth. While facing challenges in product sales and regulatory uncertainties, the company's focus on innovation and expanding its product portfolio presents opportunities for continued success in the healthcare sector.

Moderna posts strong Q1 earnings, eyes market expansion opportunities

Moderna's Q1 performance reflects strong earnings, robust R&D investments, and strategic commercial negotiations.
The company's strengths lie in market positioning, cost optimization, asset prioritization, and collaboration opportunities.
Challenges include contract timing uncertainties, market competition, and regulatory approval processes.
Amidst challenges, Moderna sees opportunities in revenue growth, market expansion, program advancements, and partnership developments.

Moderna reports Q2 performance, innovation strength, margin challenges

Moderna's Q2 performance reflects significant investments and revised COVID-19 sales expectations.
The company's strengths lie in innovation, oncology progress, and preparations for upcoming product launches.
Challenges include margin guidance revisions and differing views on vaccine development strategies.
Opportunities exist in vaccine combinations, market positioning, and accelerated enrollment in flu studies.

Moderna reports $1.8B Spikevax sales, eyes profitability in 2024

Moderna's Q3 2023 Earnings Call highlighted strong Spikevax sales, plans for new vaccine launches, and a focus on profitability. Despite challenges like restructuring charges, the company sees opportunities in expanding its product portfolio and market share.

Moderna reports $6.1B in 2023 sales, anticipates $4B in 2024

Moderna's financials reflect market transition impact with a focus on cost management.
Strong pipeline progress and confidence in vaccine efficacy milestones for 2024.
Challenges include net loss, anticipated sales decrease, and ongoing regulatory discussions.
Opportunities lie in potential vaccine approvals, partnerships, and therapeutic advancements.

Moderna reports Q1 sales dip, eyes growth in pipeline

Moderna's Q1 2024 performance reflects a shift in sales dynamics with a focus on pipeline progress and financial discipline.
While facing challenges in market dynamics and transparency, Moderna's strategic focus on COVID-19 and pipeline advancements positions it for growth.
Opportunities lie in expanding vaccine delivery methods, international market penetration, and therapeutic advancements in various programs.

Moderna reports robust Q2 earnings, focuses on innovation and cost management

Moderna's Q2 2024 earnings call highlighted strong financial performance, strategic achievements in vaccine development, and operational improvements. While facing challenges in sales and competitive pressures, the company remains focused on innovation and cost management. Opportunities lie in upcoming milestones and the potential of its diverse clinical programs.

Moderna reports robust Q3 earnings, eyes global expansion and innovation

Moderna's Q3 2024 earnings call showcased strong financial performance, cost-saving initiatives, and a robust pipeline of products in development.
While facing legal challenges and market competition, the company's strategic strengths lie in market share, global expansion plans, and financial stability.
Opportunities in education, international markets, and product development position Moderna for continued growth and innovation in the healthcare sector.
Navigating challenges and leveraging opportunities will be key for Moderna to maintain its leadership in the COVID vaccine market and drive future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rose and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Stéphane Bancel said investors funded the mRNA vaccine platform.

Moderna CEO Defends Pricing Plans for Covid Shot

Arista Networks

Copart

Garmin

Incyte

Intuitive Surgical

Monster Beverage

Monolithic Power Systems

Old Dominion Freight Line

Teradyne

Is the Fed done jacking up interest rates or not? Angst over that question is torturing the stock market — but a handful of S&P 500 stocks aren't worried.

10 S&P 500 Stocks Are Practically Immune To More Fed Rate Hikes

Moderna's multi-year run of earning billions from its COVID-19 vaccine is winding down. It still has a massive pipeline of other pharmaceutical offerings that are full of promising projects.

2 Reasons to Buy Moderna Stock, and 1 Reason to Sell

CRISPR Therapeutics

Moderna's pipeline programs may drive another huge phase of growth. The potential approval of CRISPR's first product could be a major catalyst for the stock.

Better Growth Stock: Moderna vs. CRISPR Therapeutics

We still may be able to count on Moderna for blockbuster revenue -- and over the long term.

Moderna May Be Just Getting Started in This Big Market

Axcelis Technologies

Amazon

ARK Genomic Revolution Multi-Sector ETF

Celsius Holdings

Alphabet

QUALCOMM

Target

United Rentals

Veeva Systems

These diversified growth stocks could add rocket fuel to your long-term investment portfolio.

10 Best Stocks to Buy in March 2023

NVIDIA

Tesla

Bulls piled into the nation's largest chipmaker and most valuable car company this month, with shares of each company surging about 20%.

February's Stock Winners And Losers: Tesla, Nvidia Lead Charge As Moderna Plunges

CAMBRIDGE, MA / ACCESSWIRE / February 28, 2023 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced its participation in a fireside chat at Cowen's 43rd Annual Health Care Conference on Monday, March 6th at 9:10 a.m. ET. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the Moderna website at investors.modernatx.com.

Moderna to Present at Cowen's 43rd Annual Health Care Conference

Enphase Energy

Johnson & Johnson

Meta Materials

Mullen Automotive

NextEra Energy

Pfizer

Millennial investors might think investing is easy and "stocks only go up." But a few of their popular holdings are sinking fast.

8 Sinking Stocks Wipe The Smirks Off Millennials' Faces

This vaccine leader is preparing for a post-pandemic world.

3 Crucial Things to Know About Moderna Right Now

Moderna Inc will make certain contingent development, commercial and regulatory milestone payments to the U.S. National Institutes of Health (NIH) related to the development of COVID-19 vaccines, the company said in a filing on Friday.

Moderna to make milestone payments to NIH for COVID vaccine

An investment firm sees more losses ahead for the biotech's investors.

Why Moderna Stock Dropped Today

2023 may be a year of transition for the biotech.

Does This Number Mean It's Time to Sell Moderna Stock?

Startling cancer vaccine results from Moderna could drive the company's second act and usher in the next big thing in biotech. Here's what you need to know.

The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks

Moderna stock reversed lower Thursday after the FDA granted its Merck-partnered cancer vaccine a breakthrough designation. The post Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings appeared first on Investor's Business Daily.

Moderna's Cancer Vaccine Wins An FDA Boon, But Shares Drop On Mixed Earnings

Moderna's (MRNA) fourth-quarter earnings and sales miss expectations. Management reiterates guidance to record a minimum of $5 billion from COVID vaccine sales in 2023.

Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y

Moderna, Inc. (NASDAQ:MRNA ) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Lavina Talukdar - Head, Investor Relations Stephane Bancel - Chief Executive Officer Stephen Hoge - President Arpa Garay - Chief Commercial Officer Jamey Mock - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Gena Wang - Barclays Matthew Harrison - Morgan Stanley Edward Tenthoff - Piper Sandler Michael Yee - Jefferies Tyler Van Buren - Cowen Jessica Fye - JPMorgan Ellie Merle - UBS Joseph Stringer - Needham Operator Good morning. My name is Kevin and welcome to Moderna's Fourth Quarter 2022 Earnings Call.

Moderna, Inc. (MRNA) Q4 2022 Earnings Call Transcript

When it comes to profits, the new Moderna MRNA -6.70%decrease; red down pointing triangle is about to look a lot like the old Moderna. That's spooking investors. Moderna on Thursday reported financial results that showed that in the two main Covid-19 vaccination years—2021 and 2022—the company made in excess of $20 billion in profits on more than $37 billion in revenue.

Moderna Peers Over a Scary Profit Cliff

Moderna Inc  (NASDAQ:MRNA) stock is down 7% at $147.10 at last check, after the company's lackluster fourth-quarter earnings report offset some upbeat Food and Drug Administration (FDA) news.

Moderna Stock Options Pop After Earnings, FDA Update

Moderna Therapeutics Inc (NASDAQ:MRNA) stock started Thursday sharply lower as the COVID vaccine maker reported earnings that fell short of market expectations. As demand for COVID shots has dropped the cost of production is on the up, as the drug manufacturer is left with spare capacity.

Moderna stock falls as orders for COVID shots slump

Moderna (MRNA) delivered earnings and revenue surprises of -22.53% and 0.04%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates

Moderna stock fell early Thursday after guidance for 2023 sales missed forecasts following a mixed fourth-quarter report. The post Moderna Skids After 2023 Guidance Misses By More Than $2 Billion appeared first on Investor's Business Daily.

Moderna Skids After 2023 Guidance Misses By More Than $2 Billion

Shares of the biotech company fell early Thursday, wiping out gains from positive news around its cancer vaccine candidate, as fourth-quarter earnings missed expectations.

Moderna Earnings Hit by Falling Covid Vaccine Sales

Moderna reported quarterly earnings of $3.61 per share, a 68% decrease from the same period in 2021 when it booked $11.29 per share.

Moderna misses on earnings as costs rise from surplus production capacity, lower demand for Covid shots

Demand for its Covid-19 vaccine sank from year-earlier highs when the spread of the Omicron variant boosted sales.

News for Moderna Stock (MRNA)